Skip to search formSkip to main contentSkip to account menu

danusertib

Known as: Benzamide, 4-(4-methyl-1-piperazinyl)-N-(1,4,5,6-tetrahydro-5-((2R)- methoxyphenylacetyl)pyrrolo(3,4-c)pyrazol-3-yl)- 
A small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinases, which may… 
National Institutes of Health

Related topics

Related topics

4 relations
Aurora Kinase A

Broader (2)

BenzamidesPyrazoles

Narrower (1)

PHA 739358

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Targeting hepatocarcinogenesis model in C56BL6 mice with pan-aurora kinase inhibitor Danusertib
Background: To elucidate the expression of Aurora kinases (AURK) and the anticancer effects of pan-aurora kinase inhibitor… 
2018
2018
[Effect of danusertib on cell cycle, apoptosis and autophagy of hepatocellular carcinoma HepG2 cells in vitro].
OBJECTIVE To investigate the effect of danusertib (Danu), an inhibitor of Aurora kinase, on the proliferation, cell cycle… 
2013
2013
Phase II study of danusertib (D) in advanced/metastatic non-small cell lung cancers (NSCLC).
e19138 Background: D is an ATP competitive pan-aurora kinases inhibitor with activity also against FGFRs, VEGFR, Ret, TrkA, Scr… 
2011
2011
Randomized phase II study of danusertib (D) in second-line metastatic castration-resistant prostate cancer (CRPC).
4628 Background: D is a small molecule that inhibits Aurora kinases, proteins regulating mitosis, implicated in tumorigenesis and… 
2010
2010
Phase II study of danusertib (D) in advanced/metastatic colorectal and pancreatic cancers (CRC, PC).
e13558 Background: D is a pan-aurora kinases inhibitor also active against other kinases with oncogenic potential, such as TRKA… 
2010
2010
Phase II study of danusertib (D) in advanced/metastatic breast and ovarian cancers (BC, OC).
5014 Background: D is a small molecule that inhibits a urora kinases, proteins regulating mitosis implicated in tumorigenesis and… 
2010
2010
Phase I study of danusertib (D) in combination with bevacizumab (B) in solid tumors.
3066 Background: D is a small molecule that inhibits Aurora Kinases, proteins regulating mitosis and overexpressed in many tumors… 
2009
2009
Danusertib Hydrochloride (PHA-739358), a Multi-Kinase Aurora Inhibitor, Elicits Clinical Benefit in Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia…
Abstract 864 Background: Despite the availability of novel ABL tyrosine kinase inhibitors ( TKI ) in addition to imatinib… 
2009
2009
Resistance to Danusertib (formerly PHA-739358) in BCR-ABL-Positive Cells Is Mediated by Upregulation of the Drug Transporter Abcg2 and Can Be Suppressed in Vitro by Combination Treatment with…
Abstract 1724 Poster Board I-750 The success of imatinib (IM, formerly STI571, Gleevec ® ) in the treatment of chronic myeloid… 
2009
2009
Administered as a 24-Hour Infusion with and without Granulocyte Colony-Stimulating Factor in a 14-Day Cycle in Patients with Advanced Solid Tumors
Purpose: This study was conducted to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the i.v. pan… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)